DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial (PR Newswire)
UF startup DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40... Read More